Key Highlights

  • ImmuPharma LSE:IMM was shown gaining 17.31% on 21 September 2026, putting the healthcare stock among the notable percentage movers in the displayed market data.
  • The latest corporate developments centre on P140, the company's lead autoimmune-disease programme, and its newly filed international Patent application covering the P140 precision-medicine approach.
  • ImmuPharma has also reported new preclinical research showing P140 activity in a model of metabolic dysfunction-associated steatohepatitis.
  • The company is progressing Kapiglucagon toward IND-enabling development and potential first-in-human studies.
  • ImmuPharma continues to focus on securing a commercial Partnership for P140 during 2026.
  • The sharp share-price move comes after a highly active period for LSE:IMM, with significant trading Volatility through September.

Why Is ImmuPharma LSE:IMM in Focus on 21 September 2026?

ImmuPharma LSE:IMM is attracting renewed market attention after the shares were shown rising 17.31% on 21 September 2026.

The move follows several significant developments announced during September, making P140 the main focus for investors tracking the company's drug-development pipeline.

On 15 September, ImmuPharma announced that it had filed an international Patent Cooperation Treaty application covering its P140 precision-medicine approach, including the identification and treatment of patients with the Type M immune profile. The filing builds on the company's earlier UK patent application and incorporates additional experimental data generated during the priority period.

The timing is particularly relevant because the company has described P140 as its lead asset and a core value driver.

What Is Behind the 17.31% Rise in LSE:IMM?

The precise reason for the entire 17.31% gain on 21 September has not been separately confirmed by a single company announcement.

However, the recent flow of P140-related developments provides important context for the renewed attention around LSE:IMM.

The international patent filing represents another stage in ImmuPharma's strategy to seek protection for intellectual property surrounding P140 and the Type M precision-medicine approach. The company said additional experimental work completed during the 12-month priority period was incorporated into the international filing.

Investors are also assessing the potential commercial implications because ImmuPharma continues discussions around a potential P140 partnership.

Why Is P140 So Important for ImmuPharma?

P140 is ImmuPharma's lead development programme and is being investigated primarily in autoimmune disease.

The company's strategy involves combining P140 with a Type M precision-medicine approach, designed to identify a biologically defined group of patients that may have a greater likelihood or magnitude of response.

The company has continued generating experimental data around this approach, strengthening the intellectual-property and scientific package supporting the programme.

The latest international patent filing is therefore relevant not only from an intellectual-property perspective but also because it supports ImmuPharma's broader objective of developing P140 for potential commercial partnering.

Could the New P140 Research Expand Investor Interest?

Another September development has added a further scientific dimension to the P140 story.

Peer-reviewed research from researchers associated with CNRS and the University of Strasbourg evaluated P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis, commonly known as MASH.

The study reported that treatment with P140 reduced steatohepatitis and fibrosis and improved several disease-related biological and histological measures in the experimental model.

These findings are preclinical and do not establish efficacy in humans. However, they provide additional scientific information regarding P140's biological activity outside its original autoimmune-disease development focus.

The company's primary development priority remains autoimmune disease.

What Is Happening With Kapiglucagon?

P140 is not ImmuPharma's only development programme.

The company is also advancing Kapiglucagon, a peptide-based drug candidate, toward clinical development.

During the first half of 2026, ImmuPharma completed its overall development plan for Kapiglucagon. Regulatory, manufacturing, drug-product development and bioanalytical work have subsequently moved into active execution.

Specialist development partners have been selected for different parts of the programme, with the objective of progressing toward IND-enabling activities and eventual first-in-human clinical studies.

This creates another potential source of future milestones for LSE:IMM, although the programme remains in development and has not yet reached commercialisation.

Why Is the P140 Commercial Partnership Important?

One of the most closely watched elements of the ImmuPharma story is the company's search for a commercial deal around P140.

ImmuPharma has stated that discussions are continuing with its US licensing partner, Avion Pharmaceuticals, while broader commercial partnering remains a key objective for 2026.

A potential transaction could become an important corporate catalyst because the company's development programmes require Capital and commercial resources as they advance.

Until a definitive commercial agreement is reached, however, the timing, structure and financial terms remain uncertain.

What Did ImmuPharma Report About Its Financial Position?

ImmuPharma reported an operating loss of approximately £1.1 million for the six months ended 30 June 2026, compared with £1.2 million during the same period in 2025.

The company reported a total loss of approximately £4.7 million, with a significant part of the increase attributable to a £3.36 million finance loss related to the fair-value calculation of a derivative financial asset.

Cash stood at approximately £0.7 million at 30 June 2026.

Earlier in 2026, the company completed approximately £6.47 million of gross fundraising, comprising a £6 million subscription and approximately £0.47 million from a retail offer. ImmuPharma stated that the financing, together with existing resources, was expected to provide a cash runway into the second half of 2028 based on the assumptions underlying the financing.

Why Has LSE:IMM Been So Volatile During September?

The share price has experienced substantial daily movements during September.

Available historical trading data shows LSE:IMM rising 13.88% on 17 September before falling 15.08% on 18 September.

The sequence illustrates how quickly sentiment and trading activity can shift around small-cap biotechnology companies when investors are responding to scientific, intellectual-property and corporate developments.

The 17.31% move shown for 21 September therefore continues a period of elevated volatility rather than representing an isolated change in trading behaviour.

What Are Investors Watching Next for LSE:IMM?

Several developments could remain important for ImmuPharma:

  • P140 patent progression: The international application will move through the international phase, including examination and subsequent publication processes.
  • P140 partnering: Investors will watch for progress toward a potential commercial agreement.
  • Type M research: Further scientific data could provide additional information about the precision-medicine strategy.
  • Kapiglucagon development: Regulatory, Manufacturing and bioanalytical milestones will remain relevant.
  • Clinical development: Progress toward IND-enabling work and first-in-human studies could become increasingly important.
  • Financial resources: Future expenditure and funding requirements remain relevant as both programmes advance.
  • Additional P140 research: Further evidence from autoimmune or other disease models could influence the broader scientific narrative.

Could P140 and Kapiglucagon Keep LSE:IMM in Focus?

The 17.31% gain on 21 September 2026 puts ImmuPharma back among the notable percentage movers in the displayed market data.

The company's latest developments provide several reasons for continued investor attention: international patent protection for P140, additional preclinical research, ongoing partnering discussions and the transition of Kapiglucagon into active development.

At the same time, both programmes remain subject to development, regulatory, clinical and commercial risks. The key focus now is whether upcoming milestones can provide further evidence of scientific progress and commercial potential.

For LSE:IMM, the combination of intellectual-property developments, drug-development milestones and potential partnering activity is likely to remain central to the market narrative.